Efficacy and Safety of S-1 as Monotherapy in Elderly Patients with Advanced Breast Cancer

Abstract

Objective To evaluate the efficacy and safety of S-1 monotherapy in elderly patients with advanced breast cancer.Methods Retrospectively analysis sixty-five elderly patients with advanced breast cancer.The study group(S group,n = 32):S-1:40-60 mg(l.25m~2,40 mg;1.25-1.5 m~2,50 mg;l.5 m~2,60 mg,twice/day,oral administration,d1-d14,three weeks was a cycle.The control group(X group,n = 33):Capecitabine:2 000 mg/(m~2·d),separated to twice,d1-d14,three weeks was a cycle. The efficacy and toxicity were evaluated by WHO standards after 2-cycle treatment.Results The efficacy and toxicity could be evaluated in the all 65 patients,the RR of S group and X group was 31.3%(10/32), 27.3%(9/33),the DCR was 78.1%(25/32),69.7%(23/33),the median TTP was 7.5,7.0 months, the OS was 17.3,15.2 months.There was no significant difference(P0.05).The most common toxicities of the two groups were hematological,digestive toxic reactions,stomatitis and feeble,mainly 1-2 degree, and could be well tolerated.The Hand-foot syndrome rate of X group exceeded the S group(P = 0.000).Conclusion The efficacy of S-1 for elderly patients with advanced breast cancer is significant with well-tolerated toxicity better than Capecitabine,and worth to further study and popularize.